For immediate release
Chicago, IL – February 1, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Apple Inc. AAPL, Tesla, Inc. TSLA and Johnson & Johnson JNJ.
Here are the highlights from Monday’s analyst blog:
Top analyst reports for Apple, Tesla and Johnson & Johnson
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA) and Johnson & Johnson (JNJ). These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.
You can see all today’s research reports here >>>
Shares of Apple outperformed the S&P 500 over the past year (+27.8% vs. +19.3%), with December quarter bulk results expected to help maintain momentum in the stock despite continued market volatility. The Zacks analyst believes Apple has benefited from the momentum in the Services business, strong adoption of Apple Pay and growth in the Apple Music subscriber base.
Apple’s results in the first quarter of fiscal 2022 benefited from strong iPhone sales and continued momentum in the Services business amid significant supply chain constraints. Mac also had a strong quarter thanks to strong demand for the newly redesigned MacBook Pro, powered by the M1 chip. Apple, however, did not provide second-quarter revenue guidance due to pandemic uncertainties.
(You can read the full Apple research report here >>>)
You’re here shares have gained +19.3% over the past six months against Zacks’ domestic auto industry gain of +5.9%. The Zacks analyst believes strong demand for Model 3s and Ys has buoyed Tesla’s revenue.
Tesla hit record deliveries and record gross margin in the fourth quarter. Despite the global chip crisis, Tesla’s vehicle deliveries jumped 90% in 2021. TSLA is also poised to benefit from its Shanghai gigafactory. High R&D and SG&A costs along with massive capital investment plans are likely to hurt Tesla’s margins and cash flow in the coming quarters.
(You can read the full Tesla research report here >>>)
Shares of Johnson & Johnson have gained +6.1% in the last three months against the +4.1% gain of the industry Zacks Large Cap Pharmaceuticals. The Zacks analyst believes J&J has made rapid progress with its pipeline and line extensions, with several crucial data reads and regulatory milestones expected in the near term.
The pharmaceuticals unit also outperformed the market thanks to Darzalex and Stelara and the contribution of new drugs, Erleada and Tremfya, as well as the COVID-19 vaccine. Consumer unit sales are improving, despite external supply constraints. However, headwinds such as generic competition and pricing pressure continue to weigh on margins.
(You can read the full Johnson & Johnson research report here >>>)
Other noteworthy reports we’re featuring today include Intel Corp. (INTC) and PetroChina Company Ltd. (PTR).
Zacks names ‘only one best choice for doubling up’
From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.
As one investor put it, “curing and preventing hundreds of diseases… what should this market be worth?” This company could rival or surpass other recent Zacks stocks that are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in a year.
Free: See our best stock and our 4 finalists >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.
7 best stocks for the next 30 days
Just Released: Experts distill 7 elite stocks from the current Zacks No. 1 Ranking 220 Strong Buys list. They consider these tickers “most likely for early price increases.”
Since 1988, the full list has beaten the market more than 2 times with an average gain of +25.3% per year. So be sure to give your immediate attention to these 7 handpicked ones.
Discover them now >>
Click to get this free report
Apple Inc. (AAPL): Free Inventory Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Tesla, Inc. (TSLA): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.